Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259450 · ClinicalTrials.gov registry record · Phase 1
Study to Assess AFM24 in Advanced Solid Cancers
A Phase 1 study, sponsored by Affimed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT04259450 is a Phase 1 study that was terminated before completion, run by Affimed. The registered enrollment target is 85 participants.
The verdict
NCT04259450, a Phase 1 study, was terminated before completion, sponsored by Affimed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24 is a tetravalent bispecific (anti-human EGFR x anti-human CD16A) innate immune cell engaging recombinant antibody being developed to target EGFR-expressing solid tumors and has been designed to specifically utilize the cytotoxic potential of the innate immune system, in particular natural killer cells and macrophages for the specific and efficient elimination of EGFR expressing cancer cells.
Interventions
- DRUG 14 mg AFM24
- DRUG 40 mg AFM24
- DRUG 80 mg AFM24
- DRUG 160 mg AFM24
- DRUG 320 mg AFM24
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04259450
The ClinicalTrials.gov registry entry for NCT04259450 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affimed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 14 mg AFM24 is the first listed.
NCT04259450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04259450 about?
NCT04259450 is a clinical study titled "Study to Assess AFM24 in Advanced Solid Cancers". AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24 i...
What is the current status of trial NCT04259450?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2020-04-07. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT04259450?
The interventions under investigation include: 14 mg AFM24 (DRUG), 40 mg AFM24 (DRUG), 80 mg AFM24 (DRUG), 160 mg AFM24 (DRUG), 320 mg AFM24 (DRUG).
Who is sponsoring clinical trial NCT04259450?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.